Article Sidebar

Submitted
January 10, 2026
Accepted
March 12, 2026
Published
March 30, 2026
Download
PDF
Statistic
Read Counter : 32

Main Article Content

Abstract


"For decades, emerging RNAviruses have continued to multiply and diversify constantly for humanity. Many regulations have been issued regarding different strains of coronavirus to combat human infection, and they do not cause the deaths of millions of people around the world.". Emerging RNA viruses, including coronaviruses, flaviviruses, and filoviruses, have demonstrated the ability to cause pandemics and outbreaks with devastating health and economic impacts.


Their high mutation rates and zoonotic potential complicate public health responses. This review provides a detailed overview of the epidemiological trends of major emerging RNA viruses, their mechanisms of host infection and immune evasion, and the current challenges in vaccine development. Key obstacles include antigenic variability, cross-species transmission, and limited duration of immune protection. Advances in mRNA vaccine technology, vector-based vaccines, and universal vaccine strategies are also discussed. Proactive surveillance, rapid vaccine platforms, and global collaboration are emphasized as critical components for future preparedness.


Article Details

License

Copyright (c) 2026 Zahraa Hussein Obaid, Ahmed Saleem Abbas, Lubna Abd AlmuttalibAl- Shalah, Ghazi Mohamad Ramadan (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Zahraa Hussein Obaid (2026) “Emerging RNA Viruses: Epidemiology, Pathogenesis, and Challenges for Vaccine Development: Review”, Journal of Biomedicine and Biochemistry, 5(1), pp. 36–55. doi:10.57238/jbb.2026.7432.1163.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

How to Cite

Zahraa Hussein Obaid (2026) “Emerging RNA Viruses: Epidemiology, Pathogenesis, and Challenges for Vaccine Development: Review”, Journal of Biomedicine and Biochemistry, 5(1), pp. 36–55. doi:10.57238/jbb.2026.7432.1163.
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Gogoi D, Baruah PJ, Narain K. Immunopathology of emerging and re-emerging viral infections: an updated overview. Acta Virol. 2024;68:12108. https://doi.org/10.3389/av.2024.12108.
  2. Mohapatra S, Menon NGG. Factors responsible for the emergence of novel viruses: an emphasis on SARS-CoV-2. Curr Opin Environ Sci Health. 2022;27:100358. https://doi.org/10.1016/j.coesh.2022.100358.
  3. Liu J, Dai S, Wang M, Hu Z, et al. Virus-like particle-based vaccines against emerging infectious disease viruses. Hum Vaccin Immunother. 2016;12(5):1234-1245. https://doi.org/10.1007/s12250-016-3756-y.
  4. Han JJ, Song HA, Pierson SL, Shen-Gunther J, Xia Q. Emerging infectious diseases are virulent viruses—are we prepared? An overview. Microorganisms. 2023;11(11):2618. https://doi.org/10.3390/microorganisms11112618.
  5. Hsiung KC, Chiang HJ, Reinig S, Shih SR. Vaccine strategies against RNA viruses: current advances and future directions. Vaccines (Basel). 2024;12(12):1345. https://doi.org/10.3390/vaccines12121345.
  6. Medigeshi GR, Fink K, Hegde NR. Position paper on road map for RNA virus research in India. Front Microbiol. 2018;9:1753. https://doi.org/10.3389/fmicb.2018.01753.
  7. Kautz TF, Forrester NL. RNA virus fidelity mutants: a useful tool for evolutionary biology or a complex challenge? Viruses. 2018;10(11):600. https://doi.org/10.3390/v10110600.
  8. Pollett S, Melendrez MC, Berry IM, Duchêne S, Salje H, Cummings DAT, et al. Understanding dengue virus evolution to support epidemic surveillance and counter-measure development. Infect Genet Evol. 2018;62:279-295. https://doi.org/10.1016/j.meegid.2018.04.032.
  9. Šimičić P, Židovec-Lepej S. A glimpse on the evolution of RNA viruses: implications and lessons from SARS-CoV-2. Viruses. 2022;15(1):1. https://doi.org/10.3390/v15010001.
  10. Payne S. Introduction to RNA viruses. In: Viruses. 2017. https://doi.org/10.1016/B978-0-12-803109-4.00010-6.
  11. McDonald SM, Nelson MI, Turner PE, Patton JT. Reassortment in segmented RNA viruses: mechanisms and outcomes. Nat Rev Microbiol. 2016;14(7):448-460. https://doi.org/10.1038/nrmicro.2016.46.
  12. Woolhouse MEJ, Brierley L. Epidemiological characteristics of human-infective RNA viruses. Philos Trans R Soc Lond B Biol Sci. 2018;373(1748):20170182.
  13. Wadas I, Domingues I. Systematic review of phylogenetic analysis techniques for RNA viruses using bioinformatics. Int J Mol Sci. 2025;26(5):2180. https://doi.org/10.3390/ijms26052180.
  14. Novella IS, Presloid JB, Taylor RT. RNA replication errors and the evolution of virus pathogenicity and virulence. Curr Opin Virol. 2014;9:143-147. https://doi.org/10.1016/j.coviro.2014.09.017.
  15. Burrell CJ, Howard CR, Murphy FA. Emerging virus diseases. In: Medical Virology. Elsevier; 2016. p. 217-225. https://doi.org/10.1016/B978-0-12-375156-0.00015-1.
  16. Khabbaz R, Bell BP, Schuchat A, Ostroff SM, Moseley R, Levitt A, et al. Emerging and reemerging infectious disease threats. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 2014. https://doi.org/10.1016/B978-1-4557-4801-3.00014-X.
  17. Rahman MT, Sobur MA, Islam MS, Ievy S, Hossain MJ, El Zowalaty ME, et al. Zoonotic diseases: etiology, impact, and control. Microorganisms. 2020;8(9):1405. https://doi.org/10.3390/microorganisms8091405.
  18. Topluoglu S, Taylan-Ozkan A, Alp E. Impact of wars and natural disasters on emerging and re-emerging infectious diseases. Front Public Health. 2023;11:1215929. https://doi.org/10.3389/fpubh.2023.1215929.
  19. Trovato M, Sartorius R, D’Apice L, Manco R, De Berardinis P. Viral emerging diseases: challenges in developing vaccination strategies. Front Immunol. 2020;11:2130. https://doi.org/10.3389/fimmu.2020.02130.
  20. Childs JE, Richt JA, Mackenzie JS. Introduction: conceptualizing and partitioning the emergence process of zoonotic viruses from wildlife to humans. Curr Top Microbiol Immunol. 2007.
  21. Singh RK, Dhama K, Chakraborty S, Tiwari R, Natesan S, Khandia R, et al. Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies. Vet Q. 2019;39(1):26-55. https://doi.org/10.1080/01652176.2019.1580827.
  22. Domingo E. Mechanisms of viral emergence. Vet Res. 2010;41(6):38. doi:10.1051/vetres/2010010.
  23. Marie V, Gordon ML. The (re-)emergence and spread of viral zoonotic disease. Viruses. 2023;15(8):1638. https://doi.org/10.3390/v15081638.
  24. Breman JG, Heymann DL, Lloyd G, McCormick JB, Miatudila M, Murphy FA, et al. Discovery and description of Ebola Zaire virus in 1976. J Infect Dis. 2016;214(Suppl 3):S93-S101. https://doi.org/10.1093/infdis/jiw207.
  25. Cunha MS, Costa PA, Correa IA, De Souza MR, Calil PT, Da Silva GPD, et al. Chikungunya virus: an emergent arbovirus. Front Microbiol. 2020;11:1297. doi:10.3389/fmicb.2020.01297.
  26. Ryu WS. Virus life cycle. Mol Virol Hum Pathog Viruses. 2016:31. https://doi.org/10.1016/B978-0-12-800838-6.00003-5.
  27. Walper SA, Lasarte Aragones G, Sapsford KE, Brown CW 3rd, Rowland CE, Breger JC, et al. Detecting biothreat agents. ACS Sens. 2018;3(10):1894-2024. https://doi.org/10.1021/acssensors.8b00420.
  28. Rampersad S, Tennant P. Replication and expression strategies of viruses. Viruses. 2018:55. https://doi.org/10.1016/B978-0-12-811257-1.00003-6.
  29. Lee CY. Exploring potential intermediates in cross-species transmission of influenza A. Viruses. 2024;16(7):1129. https://doi.org/10.3390/v16071129.
  30. Delves PJ. Innate and adaptive systems of immunity. In: The Autoimmune Diseases. 2020. p.45-61. https://doi.org/10.1016/B978-0-12-812102-3.00004-X.
  31. Li D, Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther. 2021;6(1):1-24. https://doi.org/10.1038/s41392-021-00687-0.
  32. Bai F, Thompson EA, Vig PJS, Leis AA. Current understanding of West Nile virus. Pathogens. 2019;8(4):193. https://doi.org/10.3390/pathogens8040193.
  33. Louten J. Virus replication. Essential Human Virology. 2016;49-70. https://doi.org/10.1016/B978-0-12-800947-5.00004-1.
  34. Idrees S, Chen H, Panth N, Paudel KR, Hansbro PM. Exploring viral–host protein interactions as antiviral therapies. Microorganisms. 2024;12(3):630. https://doi.org/10.3390/microorganisms12030630.
  35. Jeong H, Seong BL. Exploiting virus-like particles as innovative vaccines. J Microbiol. 2017;55:220-230. https://doi.org/10.1007/s12275-017-7058-3.
  36. Williams BA, Jones CH, Welch V, True JM. Outlook of pandemic preparedness. NPJ Vaccines. 2023;8(1):178. https://doi.org/10.1038/s41541-023-00773-0.
  37. Herati RS, Wherry EJ. Predictive value of animal models for vaccine efficacy. Cold Spring Harb Perspect Biol. 2018;10(4):a031583. https://doi.org/10.1101/cshperspect.a029132.
  38. Mosa AI. Antigenic variability. Front Immunol. 2020;11:2057. https://doi.org/10.3389/fimmu.2020.02057.
  39. Díaz-Salinas MA, Li Q, Ejemel M, Yurkovetskiy L, Luban J, Shen K, et al. Conformational dynamics of SARS-CoV-2 spike. Elife. 2022;11:e75433. https://doi.org/10.7554/eLife.75433.
  40. Brisse M, Vrba SM, Kirk N, Liang Y, Ly H. Emerging concepts in vaccine development. Front Immunol. 2020;11:583077. https://doi.org/10.3389/fimmu.2020.583077.
  41. Chakraborty C, Bhattacharya M, Dhama K. SARS-CoV-2 vaccines and development technologies. Vaccines (Basel). 2023;11(3):682. https://doi.org/10.3390/vaccines11030682.
  42. Cheng F, Wang Y, Bai Y, Liang Z, Mao Q, Liu D, et al. Stability of mRNA vaccines. Viruses. 2023;15(3):668. https://doi.org/10.3390/v15030668.
  43. Maslow JN. Vaccine development for emerging diseases. Vaccine. 2017;35(41):5437-5443. https://doi.org/10.1016/j.vaccine.2017.02.015.
  44. Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat Med. 2021;27(4):591-600. https://doi.org/10.1038/s41591-021-01301-0.
  45. Lundstrom K. Replicon RNA viral vectors as vaccines. Vaccines (Basel). 2016;4(4):39. https://doi.org/10.3390/vaccines4040039.
  46. Ghattas M, Dwivedi G, Lavertu M, Alameh MG. Vaccine technologies and platforms. Vaccines (Basel). 2021;9(12):1490. https://doi.org/10.3390/vaccines9121490.
  47. Boyer S, Calvez E, Chouin-Carneiro T, Diallo D, Failloux AB. Mosquito vectors of Zika virus. Microbes Infect. 2018;20(11-12):646-660. https://doi.org/10.1016/j.micinf.2018.01.006.
  48. Wang Y, Ling L, Zhang Z, Marin-Lopez A. Advances in Zika vaccine development. Vaccines (Basel). 2022;10(11):1816. https://doi.org/10.3390/vaccines10111816.
  49. Kudchodkar SB, Choi H, Reuschel EL, Esquivel R, Kwon JJA, Jeong M, et al. Synthetic DNA vaccine targeting Zika virus. Microbes Infect. 2018;20(11-12):676-684. https://doi.org/10.1016/j.micinf.2018.03.001.
  50. Ostrowsky JT, Katzelnick LC, Bourne N, Barrett AD, Thomas SJ, Diamond MS, et al. Zika virus vaccines and monoclonal antibodies. Lancet Infect Dis. 2025. https://doi.org/10.1016/S1473-3099(24)00750-3.
  51. DeZure A, Graham BS. Vaccines for emerging viral diseases. In: The Vaccine Book. 2016. p.543-560.
  52. Muyembe JJ, Pan H, Peto R, Diallo A, Touré A, Mbala-Kingebene P, et al. Ebola outbreak response with rVSV-ZEBOV-GP ring vaccination. N Engl J Med. 2024;391(24):2327-2336. https://doi.org/10.1056/NEJMoa1904387.
  53. Kumar DS, Prasanth K, Bhandari A, Jha VK, Naveen A, Prasanna M, et al. COVID-19 vaccine development challenges. Cureus. 2024;16(5):e60015. https://doi.org/10.7759/cureus.60015.
  54. Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020.
  55. Teo SP. Review of COVID-19 mRNA vaccines. J Pharm Pract. 2022;35(6):947-951. https://doi.org/10.1177/08971900211009650.
  56. Sudhan SS, Sharma P. Human viruses: emergence and evolution. In: Emerging and reemerging viral pathogens. Academic Press; 2020. p.53-68. https://doi.org/10.1016/B978-0-12-819400-3.00004-1.
  57. Voskarides K. Animal-to-human viral transitions. J Mol Evol. 2020;88(5):421-423. https://doi.org/10.1007/s00239-020-09947-z.
  58. Vashisht V, Vashisht A, Mondal AK, Farmaha J, Alptekin A, Singh H, et al. Genomics for emerging pathogen identification. BioMedInformatics. 2023;3(4):1145-1177. https://doi.org/10.3390/biomedinformatics3040069.
  59. Laxmi B, Devi PUM, Naveen T, Buddolla V. Virus-like particles for emerging viral threats. Microbe. 2025:100351. https://doi.org/10.1016/j.microb.2025.100351.
  60. Tariq H, Batool S, Asif S, Ali M, Abbasi BH. Virus-like particles as vaccine platforms. Front Microbiol. 2022;12:790121. https://doi.org/10.3389/fmicb.2021.790121.
  61. Yan D, Wei YQ, Guo HC, Sun SQ. Application of virus-like particles. Appl Microbiol Biotechnol. 2015;99:10415-10432. https://doi.org/10.1007/s00253-015-7000-8.
  62. Suphaphiphat P, Whittaker L, De Souza I, Daniels RS, Dormitzer PR, McCauley JW, et al. Antigenic characterization of influenza viruses. Vaccine. 2016;34(32):3641. https://doi.org/10.1016/j.vaccine.2016.05.031.
  63. Zapatero-Belinchón FJ, Kumar P, Ott M, Schwartz O, Sigal A. Understanding emerging viruses for pandemic preparedness. Nat Microbiol. 2024;9(9):2208-2211. https://doi.org/10.1038/s41564-024-01789-5.
  64. Gharbi J, Rezza G, Ben M'hadheb M. Emerging and re-emerging viral infections. Front Public Health. 2025;12:1528163. https://doi.org/10.3389/fpubh.2024.1528163.
  65. Holmes EC, Krammer F, Goodrum FD. Virology—The next fifty years. Cell. 2024;187(19):5128-5145. https://doi.org/10.1016/j.cell.2024.07.025.

Most read articles by the same author(s)